Sarriá-Landete Antonio J, Crespo-Matas José A, Domínguez-Quesada Inmaculada, Castellanos-Monedero Jesús J, Marte-Acosta Dinés, Arias-Arias Ángel J
Departamento de Medicina Interna, Hospital La Mancha Centro, Alcázar de San Juan, Ciudad Real, Spain.
Departamento de Neumología, Hospital La Mancha Centro, Alcázar de San Juan, Ciudad Real, Spain.
Med Clin (Engl Ed). 2022 Dec 23;159(12):557-562. doi: 10.1016/j.medcle.2022.02.028. Epub 2022 Dec 15.
Treating systemic inflammation caused by SARS-COV 2 (COVID-19) has become a challenge for the clinician. Corticosteroids have been the turning point in the treatment of this disease. Preliminary data from Recovery clinical trial raises hope by showing that treatment with dexamethasone at doses of 6 mg/day shows a reduction on morbidity in patients requiring added oxygen therapy. However, both the start day or what kind of corticosteroid, are still questions to be clarified. Since the pandemic beginning, we have observed large differences in the type of corticosteroid, dose and initiation of treatment.Our objective is to assess the predictive capacity of the characteristics of patients treated with methylprednisolone pulses to predict hospital discharge.
We presented a one-center observational study of a retrospective cohort. We included all patients admitted between 03/06/2020 and 05/15/2020 because of COVID-19. We have a total number of 1469 patients, of whom 322 received pulses of methylprednisolone. Previous analytical, radiographic, previous disease data were analyzed on these patients. The univariant analysis was performed using Chi-squared and the test of Student according to the qualitative or quantitative nature of the variables respectively. For multivariate analysis, we have used binary logistic regression and ROC curves.
The analysis resulted statistically significant in dyspnea, high blood pressure, dyslipidemia, stroke, ischemic heart disease, cognitive impairment, solid tumor, C-reactive protein (CRP), lymphopenia and d-dimer within 5 days of admission. Radiological progression and FIO input are factors that are associated with a worst prognosis in COVID-19 that receive pulses of methylprednisolone. Multivariate analysis shows that age, dyspnea and C-reactive protein are markers of hospital discharge with an area below the curve of 0.816.
In patients with methylprednisolone pulses, the capacity of the predictive model for hospital discharge including variables collected at 5 days was (area under the curve) 0.816.
治疗由SARS-CoV 2(新冠病毒)引起的全身炎症已成为临床医生面临的一项挑战。皮质类固醇一直是这种疾病治疗的转折点。“康复”临床试验的初步数据带来了希望,该数据显示,每天6毫克剂量的地塞米松治疗可降低需要额外吸氧治疗患者的发病率。然而,开始治疗的时间以及使用何种皮质类固醇仍然是有待阐明的问题。自疫情开始以来,我们观察到在皮质类固醇的类型、剂量和治疗开始时间方面存在很大差异。我们的目的是评估接受甲泼尼龙冲击治疗的患者特征对预测出院的能力。
我们开展了一项单中心回顾性队列观察研究。纳入了2020年6月3日至2020年5月15日期间因新冠病毒感染入院的所有患者。我们共有1469名患者,其中322名接受了甲泼尼龙冲击治疗。对这些患者的既往分析、影像学、既往疾病数据进行了分析。根据变量的定性或定量性质,分别使用卡方检验和学生检验进行单变量分析。对于多变量分析,我们使用了二元逻辑回归和ROC曲线。
分析结果显示,入院5天内的呼吸困难、高血压、血脂异常、中风、缺血性心脏病、认知障碍、实体瘤、C反应蛋白(CRP)、淋巴细胞减少和D-二聚体在统计学上具有显著意义。影像学进展和吸氧输入是接受甲泼尼龙冲击治疗的新冠病毒感染患者预后较差的相关因素。多变量分析表明,年龄、呼吸困难和C反应蛋白是出院的标志物,曲线下面积为0.816。
在接受甲泼尼龙冲击治疗的患者中,包括入院5天时收集的变量在内的出院预测模型的能力(曲线下面积)为0.816。